DC-CIK免疫细胞联合化疗治疗老年贲门癌临床效果分析  

The clinical efficacy of chemotherapy combined with DC-CIK cell immunotherapy in treatment of elderly patients with cardia cancer

作　　者：黎钟燕[1] 陈丽贤[2] 

机构地区：[1]广州市第一人民医院,广州市510180 [2]广州医科大学附属肿瘤医院,广州市510000

出　　处：《内科》2016年第4期515-517,共3页Internal Medicine

摘　　要：目的观察DC-CIK免疫细胞联合化疗治疗老年贲门癌的临床效果。方法选择老年贲门癌患者64例为研究对象,采用随机数字表法随机分为研究组和对照组。对照组患者30例,给予化疗;研究组患者34例,在化疗的基础上进行DC-CIK免疫细胞治疗。疗程结束后1个月,比较两组患者的治疗效果、生活质量以及不良反应发生情况,其中治疗效果采用WHO制定的肿瘤缓解评定标准评价。结果研究组患者疗效及生活质量均优于对照组(P<0.05);研究组不良反应发生率低于对照组(P<0.05)。结论 DC-CIK免疫细胞辅助治疗老年贲门癌患者可以提高疗效,值得推广应用。Objective To observe the clinical efficacy of chemotherapy combined with DC-CIK cell immunotherapy in treatment of elderly patients with cardia cancer. Methods A total of 64 elderly patients with cardia cancer were randomly divided into research group（ n = 34） and control group（ n = 30）,the control group received chemotherapy,and the research group was treated with DC-CIK cell immunotherapy on the basis of chemotherapy. A month after the treatment,the clinical efficacy,quality of life and adverse reactions were compared between two groups,and the evaluation criteria in tumors set by WHO was used to evaluated the clinical efficacy. Results The clinical efficacy and quality of life in the research group were significantly superior to those in the control group（ P〈0. 05）; the incidence rate of adverse reactions in the research group was significantly lower than that in the control group（ P〈0. 05）. Conclusions DC-CIK cell immunotherapy in adjuvant therapy of elderly cardia cancer can improve the curative effect,which is worth popularizing in clinical practice.

关 键 词：贲门癌 化疗 DC-CIK 

分 类 号：R735.2[医药卫生—肿瘤]